#United States #New York #Securities Fraud #Pomerantz LLP #Cellectis S.A.

Pomerantz Law Firm Investigates Claims on Behalf of Cellectis Investors

The Pomerantz Law Firm has initiated an investigation regarding allegations of securities fraud against Cellectis S.A. (NASDAQ: CLLS). The firm's inquiry is directed at understanding whether Cellectis, along with certain executive officers and directors, has engaged in unlawful business practices that might have impacted investor interests negatively.

This recent investigative move follows a significant announcement from Cellectis made on September 14, 2026. The company stated its decision to prioritize in vivo gene editing therapies, specifically focusing on HEAL-101 and HEAL-201. Alongside this strategic shift, Cellectis revealed its intentions to discontinue development on CAR-T cell therapies like lasme-cel and eti-cel. This abrupt change has raised questions among investors regarding the company’s financial health and strategic direction.

During a conference call held on the same day, Adrian Kilcoyne, the Chief Medical Officer of Cellectis, highlighted the firm’s struggle to finance the ongoing development of the now-suspended therapies. He noted, "Cellectis is not able [to] finance [Eti-cel and Lasme-cel] given the timelines that we have and the limited cash resources that we have." Statements like these have contributed to investor anxiety, prompting many to seek legal guidance to determine if their investments were impacted by misleading information from the company.

Following the announcement, Cellectis's American Depositary Receipt (ADR) experienced a sharp decline, plummeting $1.27 or a staggering 40.97%, closing at $1.83 per ADR. This drastic drop in stock price has placed additional scrutiny on the company, leading to questions about transparency and corporate governance.

Pomerantz LLP is recognized for its rigorous advocacy in corporate securities law, particularly for class litigation. With over 85 years of experience, the firm has a storied history of fighting for investors’ rights and striving to recover losses attributable to corporate misconduct. Founded by Abraham L. Pomerantz, a pivotal figure in the class action bar, the firm continues to reflect his dedication towards accountability in the corporate sector.

The investigation is an opportunity for affected investors to join potential class-action proceedings. Those who have endured losses due to their investments in Cellectis are encouraged to reach out to Danielle Peyton at Pomerantz LLP for further details regarding this investigation and their legal options. She can be contacted via email at [email protected] or by phone at 646-581-9980 ext. 7980.

As the situation unfolds, stakeholders are eagerly awaiting more information from Cellectis on its business strategies and financial management. The firm's next moves and adherence to legal protocols will be crucial not just for their immediate recovery but for restoring investor confidence and trust in the established firm as it continues to navigate the dynamic landscape of biotechnology and gene therapy solutions.

For more information about Pomerantz LLP and the claims against Cellectis, please visit their official website at www.pomlaw.com. It is crucial for investors to stay informed and engaged as this investigation develops, as it could yield significant implications for both the firm and its shareholders.